Abstracts

Citation

IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48. Presented at: XIX International AIDS Conference.

Citation

Size and Decay of the Resting CD4+ T Cell Latent HIV Reservoir in Early-Treated Infants. Presented at: XIX International AIDS Conference.

Citation

Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093. Presented at: XIX International AIDS Conference.

Citation

Predictors of Tuberculosis Disease in HIV-infected and HIV-exposed uninfected children from Southern Africa: IMPAACT P 1041 study. Presented at: XIX International AIDS Conference.

Citation

Association between nevirapine-resistant HIV-variants and antiretroviral treatment outcomes in single-dose nevirapine exposed infants. Presented at: XIX International AIDS Conference.

Citation

HIV-1 viral kinetics among in utero and intrapartum infected infants in NICHD HPTN 040/ PACTG 1043. Presented at: XIX International AIDS Conference.

Citation

Impact of body weight on the risk of low lopinavir/r concentrations during the third trimester of pregnancy in HIV-infected Thai and US Women. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy.

Citation

Raltegravir (RAL Pharmacokinetics (PK) and Safety in Neonates (IMPAACT P1097). Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy.

Citation

Effect of Pregnancy on Pharmacokinetics of Boosted Indinavir. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy.

Citation

Interim Results from IMPAACT P1066: Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age. Presented at: 19th Conference on Retroviruses and Opportunistic Infections.